Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, Magno F, D'Anna S E, Zanini A, Brun P, Casolari P, Chung K F, Barnes P J, Papi A, Adcock I, Balbi B
Division of Pulmonary Disease, Salvatore Maugeri Foundation, IRCCS, Veruno (NO), Italy.
Clin Exp Immunol. 2009 Aug;157(2):316-24. doi: 10.1111/j.1365-2249.2009.03965.x.
There are increased numbers of activated T lymphocytes in the bronchial mucosa of stable chronic obstructive pulmonary disease (COPD) patients. T helper type 17 (Th17) cells release interleukin (IL)-17 as their effector cytokine under the control of IL-22 and IL-23. Furthermore, Th17 numbers are increased in some chronic inflammatory conditions. To investigate the expression of interleukin (IL)-17A, IL-17F, IL-21, IL-22 and IL-23 and of retinoic orphan receptor RORC2, a marker of Th17 cells, in bronchial biopsies from patients with stable COPD of different severity compared with age-matched control subjects. The expression of IL-17A, IL-17F, IL-21, IL-22, IL-23 and RORC2 was measured in the bronchial mucosa using immunohistochemistry and/or quantitative polymerase chain reaction. The number of IL-22(+) and IL-23(+) immunoreactive cells is increased in the bronchial epithelium of stable COPD compared with control groups. In addition, the number of IL-17A(+) and IL-22(+) immunoreactive cells is increased in the bronchial submucosa of stable COPD compared with control non-smokers. In all smokers, with and without disease, and in patients with COPD alone, the number of IL-22(+) cells correlated significantly with the number of both CD4(+) and CD8(+) cells in the bronchial mucosa. RORC2 mRNA expression in the bronchial mucosa was not significantly different between smokers with normal lung function and COPD. Further, we report that endothelial cells express high levels of IL-17A and IL-22. Increased expression of the Th17-related cytokines IL-17A, IL-22 and IL-23 in COPD patients may reflect their involvement, and that of specific IL-17-producing cells, in driving the chronic inflammation seen in COPD.
在稳定期慢性阻塞性肺疾病(COPD)患者的支气管黏膜中,活化的T淋巴细胞数量增加。辅助性T细胞17(Th17)细胞在白细胞介素(IL)-22和IL-23的控制下释放IL-17作为其效应细胞因子。此外,在一些慢性炎症性疾病中Th17细胞数量会增加。为了研究白细胞介素(IL)-17A、IL-17F、IL-21、IL-22和IL-23以及Th17细胞标志物维甲酸孤儿受体RORC2在不同严重程度的稳定期COPD患者支气管活检组织中的表达情况,并与年龄匹配的对照受试者进行比较。采用免疫组织化学和/或定量聚合酶链反应检测支气管黏膜中IL-17A、IL-17F、IL-21、IL-22、IL-23和RORC2的表达。与对照组相比,稳定期COPD患者支气管上皮中IL-22(+)和IL-23(+)免疫反应性细胞数量增加。此外,与对照非吸烟者相比,稳定期COPD患者支气管黏膜下层中IL-17A(+)和IL-22(+)免疫反应性细胞数量增加。在所有吸烟者(无论有无疾病)以及仅患有COPD的患者中,支气管黏膜中IL-22(+)细胞数量与CD4(+)和CD8(+)细胞数量均显著相关。肺功能正常的吸烟者和COPD患者支气管黏膜中RORC2 mRNA表达无显著差异。此外,我们报告内皮细胞表达高水平的IL-17A和IL-22。COPD患者中Th17相关细胞因子IL-17A、IL-22和IL-23表达增加可能反映了它们以及特定的产生IL-17的细胞在驱动COPD中所见慢性炎症方面的作用。